Ibrutinib ' Treatment of Choice ' in Waldenstrom Macroglobulinemia Ibrutinib ' Treatment of Choice ' in Waldenstrom Macroglobulinemia
Longer-term results from a pivotal study have established ibritinib as one of the most effective monotherapies for this disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Hematology | Macroglobulinemia | Study | Waldenstrom's Macroglobulinemia